Active Pharmaceutical Ingredients
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 January 2013) | Viewed by 266
Special Issue Editor
Interests: pharmaceutical molecular design; selectively “targeted” pharmaceutical delivery; organic chemistry synthesis schemes; alternative pharmaceutical efficacies; additive and synergistic pharmaceutical combinations; diagnostic pharmaceuticals.
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the field of pharmacology, the spectrum of different molecular platforms that possess biological activity that impart therapeutic and diagnostic properties has markedly expanded since the early development of sulfonamide dyes as anti-bacterial agents. Besides classical small molecular weight pharmaceuticals the range of clinically relevant therapeutics now includes hormone analogs (agonists and antagonists), monoclonal immunoglobulin (e.g. anti-HER2/neu, anti-EGFR), receptor ligands, biologically active peptides (e.g. IL-2), conjugated preparations, photodynamic agents (e.g. 5-aminolevulinic acid), gene therapies (e.g. anti-sense mRNA), diagnostic dyes (e.g. methylene blue), and diagnostic imaging agents (18F-glucose), diagnostic function/response (e.g. dexamethazone, albuterol), and herbal preparations (e.g. arnica, aloe vera, ginsing). A quality that almost invariably all molecular based modalities share in common is at least one chemically active site that is responsible for their mechanism-of-action and a biological effect that is therapeutically relevant. Rarely small molecular weight pharmaceuticals like digitoxin exert multiple mechanisms-of-action which is a property that is often more frequently be seen with large molecular weight therapeutics which contain multiple different moieties where each one has a unique chemically active or biologically active site capable of evoking their own individual mechanism-of-action and biological effect (e.g. Glembatumumab vedotin, epirubicin-[anti-HER2/neu]). This special issue of Molecules welcomes previously unpublished manuscripts covering aspects about therapeutic agents pertaining to the first-time discovery or characterization of chemically active sites related to their mechanism-of-action, biological activity, physiological effect or therapeutic properties.
Prof. Dr. Cody P. Coyne
Guest Editor
Keywords
- mechanism-of-action
- chemically active site or moiety
- biologically active site or moiety
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Related Special Issue
- Active Pharmaceutical Ingredients in Molecules (1 article)
